Evidence map›Paper›PMID 29061568›Full record

Trial reportBlood2018

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Thierry Lamy, Gandhi Damaj, Pierre Soubeyran, Emmanuel Gyan, Guillaume Cartron, Krimo Bouabdallah, Rémy Gressin, Jérôme Cornillon, Anne Banos, Katell Le Du and 21 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma.International journal of radiation oncology, biology, physics · 2019
    Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Thierry LamyHematology Department, Rennes University Hospital, INSERM Research Unit 1236, Rennes, France.ORCID 0000-0002-0188-7841
Gandhi DamajHematology Department, Centre Hospitalier Universitaire (CHU) d'Amiens, INSERM U1245, Amiens, France.
Pierre SoubeyranBergonié Bordeaux Institute and Bordeaux University, Bordeaux, France.
Emmanuel GyanHematology and Cell Therapy Department, Clinical Investigation Center (CIC) INSERM U1415, CHU de Tours, Université François Rabelais, Tours, France.
Guillaume CartronHematology Department, CHU Montpellier, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5235, Montpellier, France.
Krimo BouabdallahHematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France.
Rémy GressinOnco Hematology Department, Hospital University Grenoble, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, Site Santé, La Tronche, Grenoble, France.
Jérôme CornillonHematology Department, Cancer Institute Lucien Neuwirth, Saint-Priest-en-Jarez, France.
Anne BanosHematology Department, Centre Hospitalier de la Côte Basque, Bayonne, France.
Katell Le DuHematology Department, Clinique Victor Hugo, Le Mans, France.
Mohamed BenchalalRadiotherapy Department, Centre Eugène Marquis, Rennes, France.
Marie-Pierre MolesHematology Department, CHU d'Angers, Angers, France.
Steven Le GouillHematology Department, CHU de Nantes, University of Nantes, INSERM team 10 UMR 892, Institut de Recherche en Santé de l'Université de Nantes, CIC Hospital Hôtel Dieu, Nantes, France.
Joel FleuryOncology Department, Médicale-Pôle Santé République, Clermont-Ferrand, France.
Pascal GodmerHematology Department, Centre Hospitalier de Vannes, Vannes, France.
Hervé MaisonneuveHematology Department, Centre Hospitalier Départemental de Vendée, La Roche-Sur-Yon, France.
Eric DeconinckHematology Department, Centre Hospitalier Regional Universitaire Besançon, INSERM UMR 1098, Université de Franche-Comté, Besançon, France.
Roch HouotHematology Department, Rennes University Hospital, INSERM UMR 1236, Rennes, France.
Kamel LaribiHematology Department, Centre Hospitalier du Mans, Le Mans, France.
Jean Pierre MarolleauHematology and Cell Therapy Department, CIC U1415, Department EA4666, CHU Amiens, Amiens, France.
Olivier TournilhacHematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Bernard BrangerHealth Network of Pays de Loire, Nantes, France.
Anne DevillersNuclear Medicine Department, Centre Eugène Marquis, Rennes, France.
Jean Philippe VuillezImaging Nuclear Medicine Department and Radiopharmaceutical and Bioclinical Department, CHU de Grenoble, INSERM U1039, Grenoble University, Grenoble, France.
Thierry FestINSERM UMR 1236, Rennes University, Etablissement Français du Sang and Laboratoire d'Hématologie, CHU de Rennes, Rennes, France.
Philippe ColombatHematology and Cell Therapy Department, CIC INSERM U1415, CHU de Tours, Université François Rabelais, Tours, France.
Valérie CostesPathology Department, CHU Montpellier, Montpellier, France.
Vanessa SzablewskiPathology Department, CHU Montpellier, Montpellier, France.
Marie C BénéHematology Biology, Nantes University Hospital, Nantes, France; and.
Vincent DelwailHematology and Cell Therapy Department, CIC INSERM U1415, CHU de Poitiers, and CIC INSERM 1402, Université de Poitiers, Poitiers, France.
LYSA Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controversial. We conducted a randomized trial in patients with nonbulky limited-stage DLBCL to evaluate the benefit of RT after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Patients were stratified according to the modified International Prognostic Index, including lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, age, and disease stage. The patients received 4 or 6 consecutive cycles of R-CHOP delivered once every 2 weeks, followed or not by RT at 40 Gy delivered 4 weeks after the last R-CHOP cycle. All patients were evaluated by fluorodeoxyglucose-positron emission tomography scans performed at baseline, after 4 cycles of R-CHOP, and at the end of treatment. The primary objective of the trial was event-free survival (EFS) from randomization. The trial randomly assigned 165 patients in the R-CHOP arm and 169 in the R-CHOP plus RT arm. In an intent-to-treat analysis with a median follow-up of 64 months, 5-year EFS was not statistically significantly different between the 2 arms, with 89% ± 2.9% in the R-CHOP arm vs 92% ± 2.4% in the R-CHOP plus RT arm (hazard ratio, 0.61; 95% confidence interval [CI], 0.3-1.2;

Indexed as

Antibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrednisoneProgression-Free SurvivalProspective StudiesRituximabTreatment OutcomeVincristineAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristine

Identifiers

PMID29061568
PMCPMC5757680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.